Want to see HK:1877 full AI Analyst Report?
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Ratios
Shanghai Junshi Biosciences Co., Ltd. Class H Ratios
HK:1877's free cash flow for Q3 2026 was $30.92M. For the 2026 fiscal year, HK:1877's free cash flow was decreased by $-194.94M and operating cash flow was $225.86M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.60 | 1.72 | 2.24 | 4.06 | 2.89 |
| Quick Ratio | 1.40 | 1.48 | 2.02 | 3.72 | 2.65 |
| Cash Ratio | 0.94 | 1.00 | 1.53 | 3.38 | 1.74 |
| Solvency Ratio | -0.09 | -0.21 | -0.49 | -0.77 | -0.19 |
| Operating Cash Flow Ratio | -0.17 | -0.57 | -0.81 | -1.00 | -0.32 |
| Short-Term Operating Cash Flow Coverage | -0.37 | -1.60 | -3.74 | -4.53 | -60.58 |
| Net Current Asset Value | $ -1.70B | $ -566.01M | $ 1.53B | $ 4.42B | $ 3.11B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.33 | 0.27 | 0.16 | 0.11 | 0.06 |
| Debt-to-Equity Ratio | 0.69 | 0.50 | 0.25 | 0.14 | 0.08 |
| Debt-to-Capital Ratio | 0.41 | 0.33 | 0.20 | 0.12 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.32 | 0.25 | 0.14 | 0.08 | 0.06 |
| Financial Leverage Ratio | 2.05 | 1.84 | 1.58 | 1.32 | 1.39 |
| Debt Service Coverage Ratio | -0.44 | -1.01 | -3.87 | -5.76 | -18.87 |
| Interest Coverage Ratio | -12.37 | -26.07 | -84.53 | -93.67 | -27.15 |
| Debt to Market Cap | 0.21 | 0.27 | 0.10 | 0.03 | 0.01 |
| Interest Debt Per Share | 4.20 | 3.03 | 1.84 | 1.47 | 0.73 |
| Net Debt to EBITDA | -2.55 | -0.46 | 0.92 | 1.86 | 6.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.84% | 78.92% | 55.59% | 63.79% | 68.74% |
| EBIT Margin | -37.37% | -62.21% | -163.78% | -190.09% | -17.05% |
| EBITDA Margin | -24.63% | -48.02% | -143.60% | -173.40% | -11.83% |
| Operating Profit Margin | -37.37% | -68.72% | -163.19% | -189.28% | -14.73% |
| Pretax Profit Margin | -40.89% | -69.68% | -165.71% | -184.05% | -14.72% |
| Net Profit Margin | -35.00% | -65.75% | -151.85% | -164.16% | -17.85% |
| Continuous Operations Profit Margin | -40.40% | -70.84% | -168.64% | -177.65% | -18.09% |
| Net Income Per EBT | 85.58% | 94.36% | 91.64% | 89.19% | 121.25% |
| EBT Per EBIT | 109.44% | 101.40% | 101.54% | 97.24% | 99.99% |
| Return on Assets (ROA) | -6.88% | -11.86% | -20.08% | -18.97% | -6.50% |
| Return on Equity (ROE) | -14.12% | -21.86% | -31.82% | -25.11% | -9.03% |
| Return on Capital Employed (ROCE) | -9.46% | -16.12% | -27.59% | -25.47% | -6.56% |
| Return on Invested Capital (ROIC) | -8.23% | -14.50% | -25.91% | -23.63% | -6.53% |
| Return on Tangible Assets | -7.20% | -12.46% | -20.32% | -19.14% | -6.53% |
| Earnings Yield | -4.42% | -11.95% | -13.15% | -6.07% | -1.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.66 | 3.82 | 3.11 | 5.61 | 3.10 |
| Payables Turnover | 0.46 | 1.97 | 2.57 | 1.87 | 6.41 |
| Inventory Turnover | 0.93 | 0.70 | 1.18 | 0.88 | 2.60 |
| Fixed Asset Turnover | 0.49 | 0.46 | 0.35 | 0.41 | 1.18 |
| Asset Turnover | 0.20 | 0.18 | 0.13 | 0.12 | 0.36 |
| Working Capital Turnover Ratio | 1.40 | 0.80 | 0.35 | 0.31 | 1.15 |
| Cash Conversion Cycle | -313.37 | 429.79 | 284.69 | 285.16 | 201.31 |
| Days of Sales Outstanding | 78.35 | 95.51 | 117.39 | 65.02 | 117.65 |
| Days of Inventory Outstanding | 394.13 | 519.46 | 309.57 | 415.45 | 140.58 |
| Days of Payables Outstanding | 785.85 | 185.18 | 142.26 | 195.30 | 56.92 |
| Operating Cycle | 472.48 | 614.97 | 426.96 | 480.46 | 258.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.46 | -1.46 | -2.05 | -1.94 | -0.72 |
| Free Cash Flow Per Share | -1.21 | -2.16 | -2.89 | -2.36 | -1.72 |
| Dividend Paid and CapEx Coverage Ratio | -0.62 | -1.87 | -2.31 | -4.30 | -0.71 |
| Capital Expenditure Coverage Ratio | -0.62 | -2.08 | -2.42 | -4.51 | -0.72 |
| Operating Cash Flow Coverage Ratio | -0.11 | -0.49 | -1.13 | -1.34 | -1.02 |
| Operating Cash Flow to Sales Ratio | -0.19 | -0.74 | -1.34 | -1.22 | -0.16 |
| Free Cash Flow Yield | -6.30% | -19.83% | -16.41% | -5.52% | -3.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.82 | -8.37 | -7.61 | -16.47 | -58.51 |
| Price-to-Sales (P/S) Ratio | 7.92 | 5.50 | 11.55 | 27.03 | 10.45 |
| Price-to-Book (P/B) Ratio | 3.19 | 1.83 | 2.42 | 4.14 | 5.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.87 | -5.04 | -6.09 | -18.11 | -27.51 |
| Price-to-Operating Cash Flow Ratio | -41.36 | -7.47 | -8.61 | -22.13 | -65.49 |
| Price-to-Earnings Growth (PEG) Ratio | 0.64 | 0.19 | 0.71 | -0.07 | 0.97 |
| Enterprise Value Multiple | -34.69 | -11.91 | -7.12 | -13.73 | -82.22 |
| Enterprise Value | 20.79B | 11.15B | 15.37B | 34.62B | 39.16B |
| EV to EBITDA | -34.69 | -11.91 | -7.12 | -13.73 | -82.22 |
| EV to Sales | 8.54 | 5.72 | 10.23 | 23.82 | 9.73 |
| EV to Free Cash Flow | -17.13 | -5.25 | -5.40 | -15.96 | -25.63 |
| EV to Operating Cash Flow | -44.64 | -7.77 | -7.63 | -19.50 | -61.01 |
| Tangible Book Value Per Share | 5.64 | 5.51 | 7.31 | 10.55 | 9.30 |
| Shareholders’ Equity Per Share | 6.00 | 5.95 | 7.28 | 10.36 | 8.94 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.02 | -0.02 | 0.03 | -0.23 |
| Revenue Per Share | 2.42 | 1.98 | 1.52 | 1.58 | 4.52 |
| Net Income Per Share | -0.85 | -1.30 | -2.32 | -2.60 | -0.81 |
| Tax Burden | 0.86 | 0.94 | 0.92 | 0.89 | 1.21 |
| Interest Burden | 1.09 | 1.12 | 1.01 | 0.97 | 0.86 |
| Research & Development to Revenue | 0.55 | 0.65 | 1.29 | 1.64 | 0.51 |
| SG&A to Revenue | 0.63 | 0.77 | 0.37 | 0.40 | 0.16 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.00 | 0.04 |
| Income Quality | 0.55 | 1.12 | 0.88 | 0.66 | 1.08 |
Currency in CNY
